|
1
|
Schiffman M and Solomon D: Clinical
practice. Cervical-cancer screening with human papillomavirus and
cytologic cotesting. N Engl J Med. 369:2324–2331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen PA, Jhingran A, Oaknin A and Denny
L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsikouras P, Zervoudis S, Manav B, Tomara
E, Iatrakis G, Romanidis C, Bothou A and Galazios G: Cervical
cancer: Screening, diagnosis and staging. J BUON. 21:320–325.
2016.PubMed/NCBI
|
|
5
|
Feldman CH, Liu J, Feldman S, Solomon DH
and Kim SC: Risk of high-grade cervical dysplasia and cervical
cancer in women with systemic lupus erythematosus receiving
immunosuppressive drugs. Lupus. 26:682–689. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Al-Mandeel HM, Sagr E, Sait K, Latifah HM,
Al-Obaid A, Al-Badawi IA, Alkushi AO, Salem H, Massoudi NS,
Schunemann H, et al: Clinical practice guidelines on the screening
and treatment of precancerous lesions for cervical cancer
prevention in Saudi Arabia. Ann Saudi Med. 36:313–320. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rees CP, Brhlikova P and Pollock AM: Will
HPV vaccination prevent cervical cancer? J R Soc Med. 113:64–78.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liao W, He J, Disoma C, Hu Y, Li J, Chen
G, Sheng Y, Cai X, Li C, Cheng K, et al: Hsa_circ_0107593
Suppresses the Progression of Cervical Cancer via Sponging
hsa-miR-20a-5p/93-5p/106b-5p. Front Oncol. 10:5906272021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ke L, Chen Y, Li Y, Chen Z, He Y, Liu J
and Zhuang Y: miR-142-5p promotes cervical cancer progression by
targeting LMX1A through Wnt/β-catenin pathway. Open Med (Wars).
16:224–236. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng R, Cheng X, Zhang Y, Lu X and Hu Z:
miR-214 down-regulates MKK3 and suppresses malignant phenotypes of
cervical cancer cells. Gene. 724:1441462020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu Y, Wei G, Liu L, Mo Y, Chen Q, Xu L,
Liao R, Zeng D and Zhang K: Direct targeting of MAPK8IP1 by
miR-10a-5p is a major mechanism for gastric cancer metastasis.
Oncol Lett. 13:1131–1136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu S, Gao G, Yan D, Chen X, Yao X, Guo S,
Li G and Zhao Y: Effects of miR-145-5p through NRAS on the cell
proliferation, apoptosis, migration, and invasion in melanoma by
inhibiting MAPK and PI3K/AKT pathways. Cancer Med. 6:819–833. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du Z, Wu J, Wang J, Liang Y, Zhang S,
Shang Z and Zuo W: MicroRNA-1298 is downregulated in non-small cell
lung cancer and suppresses tumor progression in tumor cells. Diagn
Pathol. 14:1322019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lang B and Zhao S: miR-486 functions as a
tumor suppressor in esophageal cancer by targeting CDK4/BCAS2.
Oncol Rep. 39:71–80. 2018.PubMed/NCBI
|
|
15
|
Wang J, Zhao X, Shi J, Pan Y, Chen Q, Leng
P and Wang Y: miR-451 suppresses bladder cancer cell migration and
invasion via directly targeting c-Myc. Oncol Rep. 36:2049–2058.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hua Y, Zhao K, Tao G, Dai C and Su Y:
miR-25 promotes metastasis via targeting FBXW7 in esophageal
squamous cell carcinoma. Oncol Rep. 38:3030–3038. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou Y, Dang J, Chang KY, Yau E, Aza-Blanc
P, Moscat J and Rana TM: miR-1298 inhibits mutant KRAS-Driven tumor
growth by repressing FAK and LAMB3. Cancer Res. 76:5777–5787. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen S, Gao C, Wu Y and Huang Z:
Identification of prognostic miRNA signature and lymph node
metastasis-related key genes in cervical cancer. Front Pharmacol.
11:5442020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsunoda K, Oikawa H, Tada H, Tatemichi Y,
Muraoka S, Miura S, Shibazaki M, Maeda F, Takahashi K, Akasaka T,
et al: Nucleus accumbens-associated 1 contributes to cortactin
deacetylation and augments the migration of melanoma cells. J
Invest Dermatol. 131:1710–1719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen F, Yin Y, Yan Z, Cao K and Zhong K:
NAC1 promotes the migration of prostate cancer cells and
participates in osteoclastogenesis by negatively regulating IFNβ.
Oncol Lett. 15:2921–2928. 2018.PubMed/NCBI
|
|
21
|
Yeasmin S, Nakayama K, Rahman MT, Rahman
M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Otuski Y, Kobayashi
H, et al: Biological and clinical significance of NAC1 expression
in cervical carcinomas: A comparative study between squamous cell
carcinomas and adenocarcinomas/adenosquamous carcinomas. Hum
Pathol. 43:506–519. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xi M and Tang W: Knockdown of Ezrin
inhibited migration and invasion of cervical cancer cells in vitro.
Int J Immunopathol Pharmacol. 34:20587384209308992020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnson CA, James D, Marzan A and Armaos
M: Cervical cancer: An overview of pathophysiology and management.
Semin Oncol Nurs. 35:166–174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vu M, Yu J, Awolude OA and Chuang L:
Cervical cancer worldwide. Curr Probl Cancer. 42:457–465. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ha SY, Yu JI, Choi C, Kang SY, Joh JW,
Paik SW, Kim S, Kim M, Park HC and Park CK: Prognostic significance
of miR-122 expression after curative resection in patients with
hepatocellular carcinoma. Sci Rep. 9:147382019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Menbari MN, Rahimi K, Ahmadi A, Elyasi A,
Darvishi N, Hosseini V, Mohammadi-Yeganeh S and Abdi M: miR-216b-5p
inhibits cell proliferation in human breast cancer by
down-regulating HDAC8 expression. Life Sci. 237:1169452019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu S, Chen Q and Wang Y: miR-125b-5p
suppresses the bladder cancer progression via targeting HK2 and
suppressing PI3K/AKT pathway. Hum Cell. 33:185–194. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hashemi ZS, Khalili S, Forouzandeh
Moghadam M and Sadroddiny E: Lung cancer and miRNAs: A possible
remedy for anti-metastatic, therapeutic and diagnostic
applications. Expert Rev Respir Med. 11:147–157. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu L, Tu H, Liang Y and Tang D: miR-218
produces anti-tumor effects on cervical cancer cells in vitro.
World J Surg Oncol. 16:2042018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park S, Eom K, Kim J, Bang H, Wang HY, Ahn
S, Kim G, Jang H, Kim S, Lee D, et al: miR-9, miR-21, and miR-155
as potential biomarkers for HPV positive and negative cervical
cancer. BMC Cancer. 17:6582017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi
S, Hanley SJB, Yue J, Watari H and Sakuragi N: Control of PD-L1
expression by miR-140/142/340/383 and oncogenic activation of the
OCT4-miR-18a pathway in cervical cancer. Oncogene. 37:5257–5268.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu X, Ju J, Liu Q, Zhu Z and Liu C: The
Chinese medicine, shezhi huangling decoction, inhibits the growth
and metastasis of glioma cells via the regulation of
miR-1298-5p/TGIF1 axis. Cancer Manag Res. 12:5677–5687. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu X, Ban Y, Zhao Z, Pan Q and Zou J:
MicroRNA-1298-3p inhibits proliferation and invasion of glioma
cells by downregulating Nidogen-1. Aging (Albany NY). 12:7761–7773.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang CM, Cheng BH, Xue QJ, Chen J and Bai
B: miR-1298 affects cell proliferation and apoptosis in C6 cells by
targeting SET domain containing 7. Int J Immunopathol Pharmacol.
30:264–271. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qiu ZK, Liu N, Zhao SF, Ding AP, Cheng G,
Qiu WS and Qi WW: miR-1298 expression correlates with prognosis and
inhibits cell proliferation and invasion of gastric cancer. Eur Rev
Med Pharmacol Sci. 22:1672–1679. 2018.PubMed/NCBI
|
|
39
|
Hu W, Wang M, Yin H, Yao C, He Q, Yin L,
Zhang C, Li W, Chang G and Wang S: MicroRNA-1298 is regulated by
DNA methylation and affects vascular smooth muscle cell function by
targeting connexin 43. Cardiovasc Res. 107:534–545. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ishibashi M, Nakayama K, Yeasmin S,
Katagiri A, Iida K, Nakayama N and Miyazaki K: Expression of a
BTB/POZ protein, NAC1, is essential for the proliferation of normal
cyclic endometrial glandular cells and is up-regulated by estrogen.
Clin Cancer Res. 15:804–811. 2009. View Article : Google Scholar : PubMed/NCBI
|
